Company intelligence / Profile preview

Anthology

Cambridge, Massachusetts, United Statesanthology.com ↗

Ownership: Private
Development stage: Commercial

Overview

Anthology has developed a proprietary platform that generates highly diversified genomes from non-model organisms—starting with filamentous fungi—to enable scalable production of bio-based products. Their technology aims to unlock new possibilities in protein manufacturing for human nutrition, animal health, and sustainable materials. No clinical results reported yet; the company is focused on R&D/platform development.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: Recombinant proteinEnzyme replacement therapyMicrobial therapy
Industry: Non-Drug Biotech

Partnerships

Not publicly disclosed.

Beyond the preview

Go deeper on Anthology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anthology.

Explore the full profile